熱門資訊> 正文

Scinai Immunotherapeutics报告财年结果

2025-05-08 05:46

Scinai Immunotherapeutics Ltd. - American Depositary Shares(SCNI) 0

Scinai Immunotherapeutics press release (NASDAQ:SCNI): FY Revenue of $0.65M.
Financial income, net in 2024, amounted to $13.5 million compared to $3.2 million for 2023. The increase was primarily due to financial income from loan conversion to equity.
Net Gain for 2024, was $4.8 million compared to net loss of $6.5 million for 2023. The increase was primarily due to $14.8 million financial income from loan conversion to equity.

More on Scinai Immunotherapeutics

Scinai Immunotherapeutics announces $10M standby equity purchase agreement
Financial information for Scinai Immunotherapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。